When will I see results from peptides?
Day three, and nothing feels different. Is it working? The honest answer depends on which clock you are watching, because the body runs several at once.
Free to join · One email when peptide care opens · Most lab results in 3–5 business days
The answer, in short
It depends on what you are measuring. In studies, hormone signals such as LH and growth hormone moved within minutes to hours, and lab markers such as IGF-1 within one to two weeks. Changes in body fat or lean mass were measured over two to twelve months. Tissue repair runs slowest, because tissues like tendon renew themselves very slowly.
Medically reviewed by Robert Lufkin, MD (opens in a new tab)
Chief Medical Officer, Vitals Vault · Updated · 17 sources
Day three, and nothing has changed
Almost everyone who starts a peptide asks the same thing in the first week. The injections are going in, the routine is set, and the mirror, the knee and the bathroom scale all look exactly as they did. Is something wrong, or is this normal?
It is usually normal, and the reason is worth understanding. A peptide is a signal. It arrives at a receptor and asks a cell to do something, release a hormone, build a blood vessel, burn a bit more fat. The asking is fast. What the cell does with that request, and how long it takes for the result to add up to something you can see or feel, depends on the tissue doing the work.
Researchers have been measuring this for decades, and the timing in their studies follows a clear pattern. Hormones respond first, often within the hour. Blood markers follow over days to weeks. Body composition shifts over months. Structural tissue like tendon runs on a clock so slow that it has to be measured in years.13914
The four clocks
It helps to think of a peptide course as four clocks running at different speeds. Each one has its own fair test of whether anything is happening.138
- 01
The signal clock (minutes to hours)
The peptide reaches its receptor and the first hormone responds. In healthy men, kisspeptin-10 raised LH within about 30 minutes. You will not feel this, but a timed blood test can see it.1
- 02
The lab clock (days to weeks)
Downstream hormones and markers settle at a new level. In older men, two weeks of GHRH(1-29) brought growth hormone and IGF-1 up to young-adult levels. This is usually the first result you can confirm.3
- 03
The function clock (weeks)
Sleep, appetite and energy shift. In a small crossover study, an oral growth hormone secretagogue increased the deepest stage of sleep within one to two weeks.8
- 04
The structure clock (months to years)
Fat, muscle, bone and connective tissue change. Trials of visceral fat, lean mass and body weight were judged at 8 weeks, 26 weeks, a year and longer.9111013
What the studies measured, and when
The table below pulls timing from the human studies behind several peptide profiles in this guide. It shows when a change was measured, which is often later than when it began. Trials pick a fixed date to judge results, so a 26-week endpoint means the change was clear by then, and says little about whether week 10 looked any different.
Notice the spread. A hormone that answers within half an hour sits in the same table as a body weight change still building at 68 weeks. Both are real results, on different clocks.
| Peptide or drug | What changed | When it was measured | Study |
|---|---|---|---|
| Kisspeptin-10 | LH rose | Within about 30 minutes | George, 2011 |
| Gonadorelin (pulsed) | LH and FSH into the normal range | Within a week | Hoffman, 1982 |
| GHRH(1-29) | Growth hormone and IGF-1 at young-adult levels | 2 weeks | Corpas, 1992 |
| CJC-1295 | IGF-1 up about 45 percent | A week after one injection | Ionescu, 2006 |
| MK-677 (oral, non-peptide) | More deep sleep | 1 to 2 weeks | Copinschi, 1997 |
| MK-677 (oral, non-peptide) | Fat-free mass up, fat unchanged | 8 weeks | Svensson, 1998 |
| Tesamorelin | Visceral fat down 15 percent vs up 5 percent on placebo | 26 weeks | Falutz, 2007 |
| Semaglutide (GLP-1) | Body weight down 14.9 percent vs 2.4 percent on placebo | 68 weeks | Wilding, 2021 |
Why hormones move fast and bodies move slowly
Hormone peptides work by nudging a gland that is already wired to respond. Gonadorelin is a copy of GnRH, the signal the hypothalamus uses to tell the pituitary to release LH and FSH. In men whose hypothalamus had stopped sending that signal, pulsed gonadorelin brought those hormones into the normal range within a week. Puberty itself, the physical result, took long-term treatment to unfold.
Kisspeptin-10, which sits one step above GnRH, shows how quickly the signal clock can run. In healthy men, LH rose within about 30 minutes of a dose. Over a 22.5-hour infusion, LH rose about fourfold and testosterone climbed by roughly 45 percent. Those are striking numbers for a single day, and they describe hormone levels in a research unit, which is a long way from any change a man would notice in his energy, mood or body.
Growth hormone peptides show the same split. GHRH-type peptides raised IGF-1 within two weeks in older adults, a quick and measurable win. But body composition lagged far behind. A six-week study of nightly GHRH in older men found no change in body composition, and a 16-week analog study found lean mass gains in men only, with IGF-1 drifting back toward baseline by the end.
MK-677, an oral compound that acts on the ghrelin receptor rather than a peptide, makes the gap easy to see. In obese men, IGF-1 rose about 40 percent and fat-free mass increased over eight weeks, while fat mass did not change. Over a year in healthy older adults, fat-free mass rose by 1.1 kg on the drug and fell by 0.5 kg on placebo.2367910
Fat and weight run on the months-long clock
Fat loss is where impatience runs highest, and where the trials are clearest about timing. Tesamorelin, a growth hormone releasing hormone analog, was tested in people with HIV and excess abdominal fat. In a 26-week trial of 412 people, visceral fat fell 15.2 percent on tesamorelin and rose 5.0 percent on placebo. A pooled analysis of two phase 3 trials found the reduction held to 52 weeks in people who stayed on it.
The GLP-1 family gives the longest view. In the STEP 1 trial of semaglutide, 1,961 adults with overweight or obesity were followed for 68 weeks. Weight fell 14.9 percent on the drug and 2.4 percent on placebo, and half the people on semaglutide lost 15 percent or more of their body weight. Those are large effects, and they were judged at well over a year.
The scale can also mislead in the other direction. In the tesamorelin trials, visceral fat, the fat packed around the organs, fell while the fat under the skin of the abdomen did not change significantly. Someone tracking only body weight could miss a meaningful shift in the kind of fat that matters most for metabolic health. A waist measurement, triglycerides and blood sugar often tell the story sooner than the number on the scale.
The lesson for anyone watching a scale is simple. Fat tissue is a slow ledger. Even the most effective peptide medicines we have were judged over many months, so a verdict on fat loss after two weeks says very little.111213
The tendon clock, and why recovery peptides need patience
Recovery peptides like BPC-157 and TB-500 get asked the timing question more than any others, and the answer starts with one of the more startling findings in sports medicine. In 2013, a Copenhagen team measured carbon-14 left in the body by nuclear bomb tests of the 1950s and 1960s, and used it to date Achilles tendon tissue from 28 people. The core of the tendon carried the carbon signature of the years when its owner was growing up. It forms during height growth, roughly the first 17 years, and is essentially not renewed after that. Muscle, sampled for comparison, showed continuous turnover.
Think about what that means for an injured tendon. The tissue you are trying to repair was largely laid down in childhood and has been coasting ever since. Any healing has to be built by the slow, sparse cells and blood vessels around it. This is why tendons heal poorly, and it is exactly the bottleneck BPC-157 targets in animal studies, by building new blood vessels into the injured area.
It also sets expectations. A 2025 systematic review of BPC-157 found 36 studies, 35 of them in animals or cells, with consistent improvements in muscle, tendon, ligament and bone healing. The one clinical report it described followed people with knee pain for months, and 7 of 12 reported relief lasting over six months after a single injection. Whatever a recovery peptide does, it does on the tendon’s schedule. Rehab, load and sleep keep working on that same schedule alongside it.1415
How to tell whether it is working
Because the clocks run at different speeds, the best early test of a peptide is rarely how you feel. It is usually a blood marker that sits on the lab clock and responds within weeks. A baseline panel before you start and a retest a few weeks in show whether the signal is landing at all, long before the mirror can.
The retest also catches the opposite problem. In the 16-week GHRH analog study, IGF-1 drifted back toward baseline by the end, which a single early test would have missed. Bodies adapt, and a second and third reading show whether a response is holding.
Feelings still count, with a caveat. Early changes in sleep or energy are real for some people, and for others they are the hopeful first week of anything new. Pairing them with numbers keeps both honest.7
- 01
Growth hormone peptides
Fasting glucose and HbA1c, since this family can raise blood sugar, alongside the IGF-1 your clinician may order.10
- 02
Reproductive peptides
LH, FSH and total testosterone or estradiol, timed with your clinician, show whether the axis is answering.2
- 03
Recovery and inflammation
hs-CRP and a structured rehab log tell you more over months than day-to-day pain does.
Where regulation stands
Since October 29, 2026, FDA allows 503A pharmacies to compound BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax for individual patients with a prescription, under enforcement discretion while final rulemaking is pending. None of the six is FDA-approved, and none has a labeled timeline for results.1617
What it means for you
If you are on day three and nothing has changed, that matches every study on this page. Signals move first and invisibly. Labs follow in weeks. Fat and muscle answer in months. Tendons, built mostly before you finished growing, answer slowest of all.
The practical plan is to decide in advance which clock you are judging and when. For a hormone peptide, that might be a lab retest at a few weeks. For body composition, a measurement at three to six months. For an injury, a rehab milestone measured over months, with the peptide as one part of the plan.
Before you start, ask your clinician one question. What result should we see, on which test, and by what date, for us to call this working? A course with that answer written down rarely drifts into wishful thinking.31114
Start with your labs
A blood test before you start and a retest after shows what actually changed for you. It is how Vitals Vault approaches every treatment.
- TestA baseline panel at Quest Diagnostics.
- DecideA licensed clinician reviews your history and results.
- RetestThe same markers again, side by side.
- HbA1cYour average blood sugar over about three months.
- Total testosteroneShows whether a reproductive-axis peptide is reaching its target, when timed with your clinician.
- hs-CRPA blood marker of inflammation you can track before and after a course.
- Liver enzymes (ALT)Part of a metabolic panel. Checks the liver before and during any new prescription.
Questions
How long do peptides take to work?
It depends on the outcome. In studies, hormone signals moved within minutes to hours and lab markers within one to two weeks. Changes in body fat or lean mass were measured over two to twelve months, and tissue repair takes longest.
How long does BPC-157 take to work?
There are no controlled human trials that define a timeline. Animal studies show faster tissue healing, and in one clinical report 7 of 12 people with knee pain had relief lasting over six months after a single injection. Tendon repair is slow by nature.
How fast do growth hormone peptides work?
IGF-1 rose within one to two weeks in several studies. Body composition changes were smaller and slower, measured over two months to a year, and one six-week study found none.
How long do peptides take to work for weight loss?
In the main trials, weight and visceral fat changes were judged at 26 to 68 weeks. GLP-1 medicines produced the largest losses. Most other peptides marketed for weight loss lack trials of that length.
Should I feel peptides right away?
Usually not. The first changes are hormonal and invisible. Some people notice sleep or appetite shifts in the first weeks, but a lab retest is a more reliable early sign than how you feel.
When should I get labs after starting peptides?
A baseline before you start, then a retest a few weeks in for hormone markers, and again at a few months for body composition goals. Your clinician sets the timing for your peptide.
Why have I not seen results from peptides?
You may be judging the wrong clock too early, the product may not contain what it claims, or the peptide may not work for that goal. A lab retest separates these, which is one reason to use a prescription and a licensed pharmacy.
Peptides, prescribed and measured
Vitals Vault is opening peptide care that starts with your blood work, is prescribed by licensed US clinicians and ends with a retest. Join the waitlist to hear first.
- Prescription only
- Licensed US clinicians
- Quest Diagnostics labs
Keep reading
Full Peptide Guide- BPC-157A 15-amino-acid peptide from a stomach protein, studied for tendon, muscle and gut repair.
- TesamorelinAn FDA-approved growth hormone releasing factor analog (Egrifta) for excess abdominal fat in adults with HIV-associated lipodystrophy.
- CJC-1295A long-acting growth hormone releasing hormone analog, studied for raising growth hormone and IGF-1.
- Kisspeptin-10The shortest active piece of kisspeptin, the brain signal that switches on the reproductive hormone axis.
- MK-677An oral, non-peptide ghrelin-receptor agonist that raises growth hormone and IGF-1. FDA lists a heart failure concern.
- Peptide cyclingDo you need to cycle peptides? What studies of receptor desensitization show, which peptides fade with constant use, and when a break backfires.
Sources
- 1. George JT, et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab. 2011 (opens in a new tab)
- 2. Hoffman AR, et al. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982 (opens in a new tab)
- 3. Corpas E, et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992 (opens in a new tab)
- 4. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 (opens in a new tab)
- 5. Ionescu M, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 (opens in a new tab)
- 6. Vittone J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997 (opens in a new tab)
- 7. Khorram O, et al. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997 (opens in a new tab)
- 8. Copinschi G, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997 (opens in a new tab)
- 9. Svensson J, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998 (opens in a new tab)
- 10. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008 (opens in a new tab)
- 11. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007 (opens in a new tab)
- 12. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 (opens in a new tab)
- 13. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021 (opens in a new tab)
- 14. Heinemeier KM, et al. Lack of tissue renewal in human adult Achilles tendon is revealed by nuclear bomb 14C. FASEB J. 2013 (opens in a new tab)
- 15. Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025 (opens in a new tab)
- 16. NCPA. FDA grants enforcement discretion for compounding six peptides. October 29, 2026 (opens in a new tab)
- 17. FDA. Bulk drug substances used in compounding under section 503A (opens in a new tab)